GHK-Cu vs BPC-157: Copper Peptide and Gastric Peptide Compared

GHK-Cu and BPC-157 are both marketed for skin and tissue repair, but they are very different molecules. GHK-Cu is a naturally occurring three-amino-acid peptide bound to copper, found in human plasma and widely used in topical skincare. BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protein. Human evidence for injecting either is minimal.

They increasingly appear together in injectable blends, sometimes alongside TB-500. That pairing hides an important split. GHK-Cu has a long history as a cosmetic ingredient applied to skin, while injected GHK-Cu and BPC-157 sit in a regulatory grey zone that FDA was still working through in 2026.

This page compares what each is, what the research shows, safety, legal status as of September 2026, and what to look for on a certificate of analysis (COA). It contains no dosing or usage instructions.

At a glance

Property	GHK-Cu	BPC-157
What it is	Copper-bound tripeptide (Gly-His-Lys)	Synthetic 15-amino-acid peptide
Natural origin	Found in human plasma, saliva and urine	Sequence from a protein in gastric juice
Main research context	Skin, wound repair and gene expression	Gut lining, tendon, ligament and muscle models
Common product forms	Topical skincare; injectable vials	Mostly injectable vials
Human evidence	Small cosmetic studies; little for injection	One uncontrolled chart review; tiny pilot
FDA compounding status	Injectable out of Category 2; panel review due by February 2027	Panel voted 8-6 in favour (July 2026), non-binding
WADA 2026	Not named	Prohibited at all times (S0, named)
Canada	Named in Health Canada’s April 2026 advisory	Named in the same advisory
Extra COA check	Copper content and heavy metals	Mass spec identity of the 15-mer

What GHK-Cu and BPC-157 are

GHK is glycyl-L-histidyl-L-lysine, a tripeptide present in human plasma, saliva and urine whose levels decline with age. It readily binds copper, and it is proposed to act mainly as that copper complex, GHK-Cu.² In cosmetics it is often listed as copper tripeptide-1.

The copper matters. Copper is an essential trace element that several enzymes need, including ones involved in building connective tissue. Part of the proposed biology of GHK-Cu is that it helps deliver copper to where tissue is being rebuilt, which is also why the metal content of a product is a quality question, not a detail.

BPC-157 is a synthetic 15-amino-acid peptide based on a protein reported in gastric juice. Preclinical work links it to growth hormone receptor expression, blood vessel growth and reduced inflammatory signalling, and in animals it is cleared quickly, with a half-life under 30 minutes.³

So one is a tiny natural peptide carrying a metal ion, the other a larger synthetic fragment with no natural counterpart in circulation. Our GHK-Cu glossary entry covers the terminology.

What the research reports and how the effects differ

Laboratory and animal studies describe GHK-Cu as stimulating collagen, elastin and glycosaminoglycan production, supporting skin fibroblasts, and promoting blood vessel and nerve outgrowth.¹ Reviews also report accelerated wound repair in rats, mice and pigs, and cite cosmetic studies reporting improvements in skin firmness, elasticity and fine lines.² Gene-expression analyses have linked GHK to changes in thousands of human genes, a finding based on database comparisons rather than clinical outcomes.²

BPC-157 research centres on the gut and the musculoskeletal system. In animal models it has been reported to improve functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injury.³

In practice, the difference is mostly about where each is used. GHK-Cu’s research base and consumer use are centred on skin, largely applied topically. BPC-157 is sold mainly as an injectable for injuries and gut complaints. Claims that injected GHK-Cu produces whole-body rejuvenation go well beyond the published evidence.

Even for skin, delivery is a real constraint. Peptides are charged, water-loving molecules, and getting them through the outer skin barrier in useful amounts is difficult; formulation strongly affects how much reaches living tissue. Our note on peptide bioavailability explains why the same molecule can behave very differently depending on how it is given.

Evidence quality: skin studies versus animal injury models

GHK-Cu’s human evidence is almost entirely cosmetic: small studies of creams and serums, often summarised in reviews rather than published as full, independent peer-reviewed trials. Much of the review literature is written by Loren Pickart, the researcher who first identified GHK in human plasma, and colleagues.¹² For injected GHK-Cu, FDA’s review found limited human data to inform safety.⁶

BPC-157’s position is similar or weaker. A 2025 systematic review found 36 relevant studies, of which 35 were preclinical and one clinical, and no clinical safety data.³ The clinical study was a retrospective knee pain chart review of 16 patients at one clinic, without a control group.⁴ A 2026 review of peptides in sports medicine concluded that many unapproved peptides look favourable in animal models but that rigorous human safety data are scarce.⁵

Cosmetic studies also have built-in limits. They tend to be short, measure appearance with imaging or instruments rather than health outcomes, and compare a finished product with its base cream, so the effect of the peptide itself is hard to isolate. Positive results support a cosmetic claim, not a medical one.

Evidence type	GHK-Cu	BPC-157
Cell and animal studies	Many, often from one research group	Many, often from one research group
Human topical or cosmetic studies	Small, mostly industry-linked	None found
Human injection studies	None found	One chart review, one two-person pilot
Head-to-head comparison	None	None

Safety, side effects and drug testing

Topical GHK-Cu has a long record as a cosmetic ingredient, and skin application is a very different exposure from injection. For injectable GHK-Cu, FDA flagged immunogenicity linked to aggregation and peptide impurities.⁶ For BPC-157, FDA flagged immunogenicity and impurities and said it lacks sufficient information to know whether the drug would cause harm in humans.⁶

Both are described in preclinical work as promoting blood vessel growth.¹³ That raises a theoretical concern for people with a current or past cancer, though GHK reviews also describe anti-cancer activity in lab studies; there are no human data either way. Any injectable copper product also deserves particular caution for people with disorders of copper metabolism, such as Wilson’s disease. Health Canada’s 2026 advisory, which names both peptides, lists infection, allergic reaction, contaminants and heavy metals among the risks of unauthorised injectables.¹¹ Our BPC-157 safety guide covers reported problems in more detail.

For athletes, WADA’s 2026 list names BPC-157 under S0 as a non-approved substance, prohibited at all times. GHK-Cu is not named, but S0 covers any substance without current government approval for human therapeutic use.¹⁰ Athletes considering an injectable product should get a ruling first. Routine workplace drug panels do not test for either.

Legal status in September 2026

BPC-157. Not FDA-approved. FDA removed it from Category 2 in April 2026, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding it to the 503A bulks list for its nominated use in ulcerative colitis.⁸⁹ The vote is non-binding and FDA must complete rulemaking first.⁹ Our report on the BPC-157 advisory vote covers the meeting.

GHK-Cu. Not FDA-approved as a drug. In April 2026 FDA removed injectable GHK-Cu from Category 2 and non-injectable GHK-Cu from Category 1, with both due to go before the advisory committee by the end of February 2027, alongside LL-37, dihexa, PEG-MGF and melanotan II.⁷⁹ Until then, neither form has a settled compounding route. Skincare containing copper peptides is sold as cosmetics, which may not claim to treat any condition. Our 503A bulks list explainer sets out the process. State rules vary.

UK. Neither is a licensed medicine; copper peptides appear in cosmetics. Canada. Health Canada’s April 2026 advisory named both BPC-157 and GHK-Cu among unauthorised injectable peptides.¹¹

Research use only labels and what a COA should show

Injectable GHK-Cu and BPC-157 are usually sold as research use only. FDA’s March 2026 warning letter to a peptide seller said such labels did not change the finding that products were intended for human use.¹² Health Canada says the same.¹¹ Our guide to what research use only means explains the loophole.

For either peptide, a credible COA should show:

• HPLC purity with the chromatogram.
• Mass spectrometry identity matching the expected molecule.
• For GHK-Cu, copper content and heavy metals testing, since the product is deliberately a metal complex.
• Endotoxin and sterility results for anything intended for injection.
• A lot number matching the vial, the laboratory’s name and a recent date. Blends need results for every component.

Three-peptide blends are a particular problem. A single purity figure for a mixture says little about whether each ingredient is present in the stated amount. Ask for separate identity and quantity results for each one.

A cosmetic product is not tested to injectable standards and should never be treated as one. It is worth contacting the laboratory named on a certificate to confirm it issued that report for that lot.

Frequently asked questions

Is GHK-Cu or BPC-157 better for skin?

They have not been compared. GHK-Cu has laboratory work and small cosmetic studies focused on skin, mostly with topical products.² BPC-157 research focuses on the gut and musculoskeletal injuries, and we found no human skin studies.³ Neither is approved to treat any skin condition, and cosmetic findings do not tell you what an injection would do.

Can GHK-Cu and BPC-157 be used together?

Blends combining them, sometimes with TB-500, are heavily marketed, but we found no controlled human study of the combination. Each has minimal human data on its own, and FDA has flagged immunogenicity concerns for both injectable forms.⁶ Combining products multiplies the purity and contamination questions. We do not give usage guidance.

Is topical GHK-Cu the same as injectable GHK-Cu?

The molecule is the same, but the exposure, regulation and risks are not. Topical copper peptides are sold as cosmetics. Injectable GHK-Cu is an unapproved drug in the US, and FDA cited immunogenicity concerns and limited human data when reviewing it.⁶ Its compounding status is due to be reviewed by February 2027.⁷

Is GHK-Cu natural?

GHK occurs naturally in human plasma, saliva and urine, and its levels fall with age.² The GHK-Cu in skincare and vials, however, is made synthetically. Natural occurrence does not make a concentrated injectable product safe, and FDA has cited immunogenicity concerns and limited human data for injectable GHK-Cu.⁶

Is GHK-Cu legal in the US?

As a cosmetic ingredient in skincare, yes, provided products make no drug claims. As an injectable, it is not FDA-approved. FDA removed injectable GHK-Cu from its Category 2 safety list in April 2026 pending an advisory committee review due by February 2027, so there is no settled compounding route yet.⁷⁹

Is GHK-Cu banned by WADA?

GHK-Cu is not named on WADA’s 2026 Prohibited List, unlike BPC-157, which is named under S0. However, S0 covers any pharmacological substance with no current government approval for human therapeutic use.¹⁰ Athletes should seek a ruling from their anti-doping organisation before using an injectable product.

Sources

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. DOI: 10.3390/ijms19071987. PMID: 29986520. pubmed.ncbi.nlm.nih.gov
2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. DOI: 10.1155/2015/648108. PMID: 26236730. pubmed.ncbi.nlm.nih.gov
3. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. DOI: 10.1177/15563316251355551. PMID: 40756949. pubmed.ncbi.nlm.nih.gov
4. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435. pubmed.ncbi.nlm.nih.gov
5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. DOI: 10.1007/s40279-026-02437-0. PMID: 41966639. pubmed.ncbi.nlm.nih.gov
6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page updated 22 April 2026. fda.gov
7. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. April 2026. frierlevitt.com
8. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda and materials). fda.gov
9. McDermott. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. 27 July 2026. mcdermottlaw.com
10. World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances; S2 Peptide hormones, growth factors, related substances and mimetics). wada-ama.org
11. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Public advisory, 9 April 2026. recalls-rappels.canada.ca
12. U.S. Food and Drug Administration, CDER. Warning Letter: Gram Peptides (MARCS-CMS 721806). 31 March 2026. fda.gov

Editorial note: This article is for general information only and is not medical or legal advice. GHK-Cu and BPC-157 have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.